District Of Columbia is currently home to 920 active clinical trials, seeking participants for engagement in research studies. These trials take place at a variety of cities in the state, including Washington, Washington, D.C., Washington DC and Washington, Dc. Whether you're a healthy volunteer interested in paid medical research or someone seeking trials related to a specific condition, the state offers a diverse array of opportunities in your vicinity.
Primary Unloading and Delayed Reperfusion in ST-Elevation Myocardial Infarction: The STEMI-DTU Trial
NCT03947619
Recruiting
The purpose of this research study is to evaluate whether using the the IMPELLA® CP System temporary circulatory assist device for 30 minutes prior to a catheterization procedure has the potential to reduce the damage to the heart caused by a heart attack, compared to the current standard of care.
Gender:
All
Ages:
Between 18 years and 85 years
Trial Updated:
06/10/2024
Locations: George Washington University, Washington, District of Columbia
Conditions: ST Elevation (STEMI) Myocardial Infarction of Anterior Wall
Register for Updates
Implementing Models for Mechanical Circulatory Support Presurgical Assessment in Congenital Heart Disease Treatment
NCT03891160
Recruiting
The purpose of this research study is to look at the advantages of using a 3D printed heart model for surgical planning in children who have been diagnosed with Congenital Heart Disease (CHD) and clinical heart failure and will undergo a ventricular assist device (VAD) placement. The investigators want to study the correlation of having a 3D printed model with improvement in patient outcomes and compare those with patients who have had a VAD placement without a 3D model.
Gender:
All
Ages:
All
Trial Updated:
06/10/2024
Locations: Children's National Hospital, Washington, District of Columbia
Conditions: Congenital Heart Disease
Register for Updates
Study of Efficacy and Safety of Tisagenlecleucel in HR B-ALL EOC MRD Positive Patients
NCT03876769
Recruiting
This is a single arm, open-label, multi-center, phase II study to determine the efficacy and safety of tisagenlecleucel in de novo HR pediatric and young adult B-ALL patients who received first-line treatment and are EOC MRD positive. The study will have the following sequential phases: screening, pre-treatment, treatment & follow-up, and survival. After tisagenlecleucel infusion, patient will have assessments performed more frequently in the first month and then at Day 29, then every 3 months f... Read More
Gender:
All
Ages:
Between 1 year and 25 years
Trial Updated:
06/10/2024
Locations: Childrens National Hospital, Washington, District of Columbia
Conditions: B-Cell Acute Lymphoblastic Leukemia
Register for Updates
ACURATE IDE: Safety and Effectiveness Study of ACURATE Valve for Transcatheter Aortic Valve Replacement
NCT03735667
Recruiting
To evaluate safety and effectiveness of the ACURATE Transfemoral Aortic Valve System for transcatheter aortic valve replacement (TAVR) in subjects with severe native aortic stenosis who are indicated for TAVR.
Gender:
All
Ages:
All
Trial Updated:
06/10/2024
Locations: MedStar Washington Hospital Center, Washington, District of Columbia
Conditions: Aortic Stenosis
Register for Updates
Platform Clinical Study for Conquering Scleroderma
NCT06195072
Recruiting
The goal of this clinical trial is to test efficacy of different investigational products (IPs) compared with placebo on the change from baseline to the end of the treatment period at Week 52 in lung capacity in participants with Interstitial Lung Disease Secondary to Systemic Sclerosis.
Gender:
All
Ages:
18 years and above
Trial Updated:
06/07/2024
Locations: Georgetown University Medical Center - Department of Rheumatology, Washington, District of Columbia
Conditions: Interstitial Lung Disease Due to Systemic Disease, Scleroderma
Register for Updates
Sacituzumab Tirumotecan (MK-2870) in Post Platinum and Post Immunotherapy Endometrial Cancer (MK-2870-005)
NCT06132958
Recruiting
The primary objectives of this study are to compare sacituzumab tirumotecan to Treatment of Physician's Choice (TPC) with respect to progression-free survival (PFS) per response evaluation criteria in solid tumors (RECIST 1.1), as assessed by blinded independent central review (BICR), and overall survival (OS). The primary hypotheses are that sacituzumab tirumotecan is superior to TPC with respect to PFS per RECIST 1.1, as assessed by BICR, and that sacituzumab tirumotecan is superior to TPC wit... Read More
Gender:
Female
Ages:
18 years and above
Trial Updated:
06/07/2024
Locations: MedStar Washington Hospital Center ( Site 4108), Washington, District of Columbia
Conditions: Endometrial Cancer
Register for Updates
A Study to Investigate The Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of RO7486967 in Participants With Early Idiopathic Parkinson's Disease
NCT05924243
Recruiting
This is a multi-center, randomized, double blind, adaptive, parallel-group, placebo controlled Phase 1b study to evaluate the safety, tolerability, pharmacokinetic (PK) and pharmacodynamics of RO7486967 in participants with idiopathic PD at the early stage of the disease (modified H&Y stage ≤2.5) who are either treatment-naïve or on stable treatment with symptomatic therapy (levodopa and/or pramipexole, ropinirole, rotigotine).
Gender:
All
Ages:
Between 40 years and 85 years
Trial Updated:
06/07/2024
Locations: Georgetown University, Washington, District of Columbia
Conditions: Parkinson Disease
Register for Updates
A Study Evaluating Atezolizumab and Bevacizumab, With or Without Tiragolumab, in Participants With Untreated Locally Advanced or Metastatic Hepatocellular Carcinoma (IMbrave152)
NCT05904886
Recruiting
The purpose of this study is to assess the efficacy and safety of tiragolumab, an anti-TIGIT monoclonal antibody, when administered in combination with atezolizumab and bevacizumab as first-line treatment, in participants with unresectable, locally advanced or metastatic hepatocellular carcinoma (HCC).
Gender:
All
Ages:
18 years and above
Trial Updated:
06/07/2024
Locations: MedStar Washington Hosp Center, Washington, District of Columbia
Conditions: Carcinoma, Hepatocellular
Register for Updates
GENERATION HD2. A Study to Evaluate the Safety, Biomarkers, and Efficacy of Tominersen Compared With Placebo in Participants With Prodromal and Early Manifest Huntington's Disease.
NCT05686551
Recruiting
This study will evaluate the safety, biomarkers, and efficacy of tominersen compared with placebo in participants with prodromal and early manifest Huntington's Disease.
Gender:
All
Ages:
Between 25 years and 50 years
Trial Updated:
06/07/2024
Locations: Georgetown University; Research Division, Psychiatry, Washington, District of Columbia
Conditions: Huntington Disease
Register for Updates
A Study to Evaluate Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Preliminary Anti-tumor Activity of RO7616789 in Advanced Small Cell Lung Cancer and Other Neuroendocrine Carcinomas
NCT05619744
Recruiting
The purpose of this study is to evaluate the safety, tolerability, pharmacokinetics (PK), pharmacodynamics (PD) and preliminary anti-tumor activity of RO7616789. The study will have 3 parts: Dose Escalation (Parts 1 and 2) and Dose Expansion (Part 3). Participants with advanced stage small cell lung cancer (SCLC) and neuroendocrine carcinoma (NEC) will be enrolled in the study.
Gender:
All
Ages:
18 years and above
Trial Updated:
06/07/2024
Locations: Georgetown Uni Medical Center; Lombardi Cancer Center, Washington, District of Columbia
Conditions: Small Cell Lung Cancer, Neuroendocrine Carcinoma
Register for Updates
DAY101 vs. Standard of Care Chemotherapy in Pediatric Patients With Low-Grade Glioma Requiring First-Line Systemic Therapy (LOGGIC/FIREFLY-2)
NCT05566795
Recruiting
This is a 2-arm, randomized, open-label, multicenter, global, Phase 3 trial to evaluate the efficacy, safety, and tolerability of tovorafenib monotherapy versus standard of care (SoC) chemotherapy in patients with pediatric low-grade glioma (LGG) harboring an activating rapidly accelerated fibrosarcoma (RAF) alteration requiring front-line systemic therapy.
Gender:
All
Ages:
25 years and below
Trial Updated:
06/07/2024
Locations: Children's National Medical Center, Washington, District of Columbia
Conditions: Low-grade Glioma
Register for Updates
Extension Study of Pimavanserin in Irritability Associated With Autism Spectrum Disorder
NCT05555615
Recruiting
52-week, open-label extension study of double-blind study ACP-103-069 to determine the long-term safety and tolerability of pimavanserin for the treatment of irritability associated with ASD in children and adolescents (aged 5 to 17 years). ACP-103-069 is a 6-week, randomized, double-blind, fixed-dose, placebo controlled, parallel group study of pimavanserin in children and adolescents with irritability associated with autism spectrum disorder (ASD).
Gender:
All
Ages:
Between 5 years and 18 years
Trial Updated:
06/07/2024
Locations: Children's Research Institute, Washington, District of Columbia
Conditions: Irritability Associated With Autism Spectrum Disorder
Register for Updates